Emergent BioSolutions Inc. Form 8-K Filing

Emergent BioSolutions Inc. filed a Form 8-K on September 14, 2026, reporting on their participation in the H.C. Wainwright 28th Annual Global Investment Conference. President and CEO Joseph C. Papa presented, discussing the company's public health initiatives, product portfolio including smallpox, anthrax, opioid overdose, botulism, and mpox treatments. The presentation highlighted strategic manufacturing capabilities, a multi-year transformation plan focused on growth and efficiency, and updates on the naloxone and MCM (Medical Countermeasures) businesses. Financial performance for YTD 2026 was reviewed, with revised full-year guidance indicating expected revenues between $645-$675 million and a net loss of $(245)-(225) million. The company is focusing on international MCM growth, internal R&D, and debt management, including bond repurchases and term loan refinancing. Key catalysts for future growth include advancing R&D programs, expanding the naloxone business, and pursuing international MCM opportunities.